following a second resubmission assessed under the orphan medicine process:
mercaptamine (Procysbi®) is not recommended for use within NHSScotland.
Indication under review: treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.
A phase III, open-label, crossover study demonstrated that extended-release mercaptamine (Procysbi®) was non-inferior to immediate-release mercaptamine in control of white blood cell cystine levels in patients with nephropathic cystinosis who were previously controlled on mercaptamine therapy.
The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice881KB (PDF)
- Medicine name:
- mercaptamine (Procysbi)
- SMC ID:
Treatment of proven nephropathic cystinosis (NC). Mercaptamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of NC patients and, when treatment is started early, it delays the development of renal failure.
- Pharmaceutical company
- Chiesi Limited
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Not recommended
- Date advice published
- 13 November 2023